A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
Clinical trial NCT04083196 · COMPLETED
Trial details
- NCT number
- NCT04083196
- Sponsor
- National Vaccine and Serum Institute, China
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-07
- Primary completion
- 2021-10-13
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.